[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629971":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":106,"collaborators":29,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":29,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":116,"minAge":117,"maxAge":29,"enrollmentInfo":118,"targetDuration":29,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":132,"whyStopped":29,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"CHA Vaccine Institute Co., Ltd.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"CVI-VZV-001 Low Dose","EXPERIMENTAL","Participants receive two doses of the investigational herpes zoster vaccine CVI-VZV-001 at the low dose level administered intramuscularly on Day 0 and Week 8.",[13],"Biological: CVI-VZV-001",{"label":15,"type":10,"description":16,"interventionNames":17},"CVI-VZV-001 High Dose","Participants receive two doses of the investigational herpes zoster vaccine CVI-VZV-001 at the high dose level administered intramuscularly on Day 0 and Week 8.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Shingrix","ACTIVE_COMPARATOR","Participants receive two doses of the licensed herpes zoster vaccine Shingrix administered intramuscularly on Day 0 and Week 8.",[23],"Biological: Shingrix",[25,30],{"type":26,"name":19,"description":27,"armGroupLabels":28,"otherNames":29},"BIOLOGICAL","Licensed herpes zoster vaccine used as an active comparator.",[19],null,{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"CVI-VZV-001","Investigational herpes zoster vaccine.",[15,9],[35],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},"Jinsol Lee","CONTACT","+82-31-881-7716","jsleee@chabio.com",[41,54,65,70,81,92,99],{"facility":42,"status":29,"city":43,"state":43,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Kyungpook National University Chilgok Hospital","Daegu","South Korea",{"type":46,"coordinates":47},"Point",[48,49],128.59111,35.87028,{"lat":49,"lon":48},[52],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},"Study Coordinator",{"facility":55,"status":29,"city":56,"state":57,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"CHA Bundang Medical Center","Seongnam-si","Gyeonggi-do",{"type":46,"coordinates":59},[60,61],127.13778,37.43861,{"lat":61,"lon":60},[64],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"facility":66,"status":29,"city":67,"state":57,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":29,"geoPoint":29,"contacts":68},"Yongin Severance Hospital, Yonsei University Health System","Yongin",[69],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"facility":71,"status":29,"city":72,"state":73,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Jeonbuk National University Hospital","Jeonju","Jeollabuk-do",{"type":46,"coordinates":75},[76,77],127.14889,35.82194,{"lat":77,"lon":76},[80],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"facility":82,"status":29,"city":83,"state":83,"zip":84,"country":44,"countryCode":29,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"The Catholic University of Korea Eunpyeong St. Mary's Hospital","Seoul","03312",{"type":46,"coordinates":86},[87,88],126.9784,37.566,{"lat":88,"lon":87},[91],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"facility":93,"status":29,"city":83,"state":83,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Chung-Ang University Hospital",{"type":46,"coordinates":95},[87,88],{"lat":88,"lon":87},[98],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"facility":100,"status":29,"city":83,"state":83,"zip":29,"country":44,"countryCode":29,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},"Ewha Womans University Seoul Hospital",{"type":46,"coordinates":102},[87,88],{"lat":88,"lon":87},[105],{"name":53,"role":37,"phone":29,"phoneExt":29,"email":29},{"type":107,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100629971","phase-2-safety-and-immunogenicity-of-cvi-vzv-001-in-adults-aged-50-years-and-above-100629971",false,"NCT07481604","Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above","A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Healthy adults aged 50 years or older\n  * Able to understand the study procedures and provide written informed consent\n  * Females and males of reproductive potential must agree to use medically acceptable contraception until 3 months after the last vaccination\n  * Females of childbearing potential must have a negative pregnancy test prior to vaccination\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * History of herpes zoster prior to screening\n  * History of severe allergic reaction to vaccines or vaccine components\n  * Known immunodeficiency or immune dysfunction\n  * Prior vaccination with varicella or herpes zoster vaccine\n  * Use of immunosuppressive therapy or systemic steroids that may affect immune response\n  * Positive test for HCV, HBV, or HIV at screening\n  * Pregnant or breastfeeding women\n  * Any medical condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation",true,"ALL","50 Years",{"count":119,"type":120},135,"ESTIMATED","INTERVENTIONAL",[123],"PHASE2","To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.",[126],"Herpes Zoster",[128,129,130,131],"Herpes Zoster Vaccine","Shingles","Varicella Zoster Virus","Immunogenicity","NOT_YET_RECRUITING","2026-03-16",{"date":135,"type":136},"2026-03-19","ACTUAL",{"date":138,"type":120},"2026-04",{"date":140,"type":120},"2027-01",{"name":5,"class":6},7]